Title: AN ACT REVISING PRIOR AUTHORIZATION LAWS; PROHIBITING PRIOR AUTHORIZATION FOR ORAL
Official Title: AN ACT REVISING PRIOR AUTHORIZATION LAWS; PROHIBITING PRIOR AUTHORIZATION FOR ORAL
Number of Sections: 4
Source: versions - HB0399_X(1).pdf
Media Type: application/pdf
Strikethrough Detection: 3 sections found

================================================================================

Section 1:
- 2025
69th Legislature 2025 HB 399
AND INHALED GENERIC PRESCRIPTION DRUGS; PROHIBITING PRIOR AUTHORIZATION FOR INHALED
PRESCRIPTION DRUGS FOR ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, OR CHRONIC
LUNG DISEASE; PROHIBITING PRIOR AUTHORIZATION FOR INSULIN; REQUIRING INSURERS TO
PROVIDE A LIST OF REASONABLE THERAPEUTIC ALTERNATIVES IF THE INSURER MAKES AN
ADVERSE DETERMINATION FOR A PRESCRIPTION DRUG; AND AMENDING SECTION 33-32-221, MCA.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:

Section 2:
Section 1. Section 33-32-221, MCA, is amended to read:
"33-32-221. Prior authorization requirements. (1) A health insurance issuer or an entity that it
contracts with to perform prior authorization on its behalf may not perform prior authorization on benefits for:
(a) any generic prescription drug that is not included in subsections (1)(d) through (1)(g) and that is
not listed within any of the schedules of controlled substances found at 21 CFR 1308.11 through 21 CFR

Section 3:
1308.15 or the schedules of controlled substances found in Title 50, chapter 32, after a covered person has
been prescribed the covered drug at the same quantity without interruption for 6 months;
(b) any prescription drug or drugs, generic or brand name, on the grounds of therapeutic
duplication for the same drug if the covered person has already been subject to prior authorization on the
grounds of therapeutic duplication for the same dosage of the prescription drug or drugs and coverage of the
prescription drug or drugs was approved;
(c) any prescription drug, generic or brand name, solely because the dosage of the medication for
the covered person has been adjusted by the prescriber of the prescription drug, as long as the dosage is
within the dosage approved by the food and drug administration or is consistent with clinical dosing for the
medication; or
- 1 - Authorized Print Version – HB 399
ENROLLED BILL
- 2025
69th Legislature 2025 HB 399
(d) any prescription drug, generic or brand name, that is a long-acting injectable antipsychotic;
(e) any formulary oral or inhaled nonbiologic generic prescription drug that is not listed as a
specialty tier drug by medicare Part D, or within any of the schedules of controlled substances found at 21 CFR

Section 4:
1308.11 through 21 CFR 1308.15 or the schedules of controlled substances found in Title 50, chapter 32;
(f) any formulary nonspecialty inhaled prescription drug, generic or brand name, for the treatment
of asthma, chronic obstructive pulmonary disease, or chronic lung disease; or
(g) formulary generic or brand name insulin for patients diagnosed with diabetes.
(2) Any adverse determination for a prescription drug made during prior authorization by a health
insurance issuer or an entity that it contracts with to perform prior authorization on its behalf must be made by a
physician whose specialty focuses on the diagnosis and treatment of the condition for which the prescription
drug was prescribed to treat, provided that prior authorization that does not result in an adverse determination
does not require the involvement of a physician on the part of a health insurance issuer or an entity that it
contracts with to perform prior authorization on its behalf.
(3) If the health insurance issuer or an entity that it contracts with to perform prior authorization on
its behalf makes an adverse determination for a prescription drug during prior authorization, it shall provide a
written adverse determination notice that includes a list of reasonable therapeutic alternatives that are covered
by the insurer's formulary."
- END -
- 2 - Authorized Print Version – HB 399
ENROLLED BILL
I hereby certify that the within bill,
HB 399, originated in the House.
___________________________________________
Chief Clerk of the House
___________________________________________
Speaker of the House
Signed this _______________________________day
of____________________________________, 2025.
___________________________________________
President of the Senate
Signed this _______________________________day
of____________________________________, 2025.
HOUSE BILL NO. 399
INTRODUCED BY J. KARLEN, V. RICCI, E. BUTTREY, J. ETCHART
AN ACT REVISING PRIOR AUTHORIZATION LAWS; PROHIBITING PRIOR AUTHORIZATION FOR ORAL
AND INHALED GENERIC PRESCRIPTION DRUGS; PROHIBITING PRIOR AUTHORIZATION FOR INHALED
PRESCRIPTION DRUGS FOR ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, OR CHRONIC
LUNG DISEASE; PROHIBITING PRIOR AUTHORIZATION FOR INSULIN; REQUIRING INSURERS TO
PROVIDE A LIST OF REASONABLE THERAPEUTIC ALTERNATIVES IF THE INSURER MAKES AN
ADVERSE DETERMINATION FOR A PRESCRIPTION DRUG; AND AMENDING SECTION 33-32-221, MCA.
[DELETED:  H-  P)a)a)a]
[DELETED:  H- )a)a)a)f)A)I]
[DELETED:  D P P A F I R I T A L O R T A I T I M A]


================================================================================

Raw Text:
- 2025
69th Legislature 2025 HB 399
AN ACT REVISING PRIOR AUTHORIZATION LAWS; PROHIBITING PRIOR AUTHORIZATION FOR ORAL
AND INHALED GENERIC PRESCRIPTION DRUGS; PROHIBITING PRIOR AUTHORIZATION FOR INHALED
PRESCRIPTION DRUGS FOR ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, OR CHRONIC
LUNG DISEASE; PROHIBITING PRIOR AUTHORIZATION FOR INSULIN; REQUIRING INSURERS TO
PROVIDE A LIST OF REASONABLE THERAPEUTIC ALTERNATIVES IF THE INSURER MAKES AN
ADVERSE DETERMINATION FOR A PRESCRIPTION DRUG; AND AMENDING SECTION 33-32-221, MCA.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
Section 1. Section 33-32-221, MCA, is amended to read:
"33-32-221. Prior authorization requirements. (1) A health insurance issuer or an entity that it
contracts with to perform prior authorization on its behalf may not perform prior authorization on benefits for:
(a) any generic prescription drug that is not included in subsections (1)(d) through (1)(g) and that is
not listed within any of the schedules of controlled substances found at 21 CFR 1308.11 through 21 CFR
1308.15 or the schedules of controlled substances found in Title 50, chapter 32, after a covered person has
been prescribed the covered drug at the same quantity without interruption for 6 months;
(b) any prescription drug or drugs, generic or brand name, on the grounds of therapeutic
duplication for the same drug if the covered person has already been subject to prior authorization on the
grounds of therapeutic duplication for the same dosage of the prescription drug or drugs and coverage of the
prescription drug or drugs was approved;
(c) any prescription drug, generic or brand name, solely because the dosage of the medication for
the covered person has been adjusted by the prescriber of the prescription drug, as long as the dosage is
within the dosage approved by the food and drug administration or is consistent with clinical dosing for the
medication; or
- 1 - Authorized Print Version – HB 399
ENROLLED BILL

- 2025
69th Legislature 2025 HB 399
(d) any prescription drug, generic or brand name, that is a long-acting injectable antipsychotic;
(e) any formulary oral or inhaled nonbiologic generic prescription drug that is not listed as a
specialty tier drug by medicare Part D, or within any of the schedules of controlled substances found at 21 CFR
1308.11 through 21 CFR 1308.15 or the schedules of controlled substances found in Title 50, chapter 32;
(f) any formulary nonspecialty inhaled prescription drug, generic or brand name, for the treatment
of asthma, chronic obstructive pulmonary disease, or chronic lung disease; or
(g) formulary generic or brand name insulin for patients diagnosed with diabetes.
(2) Any adverse determination for a prescription drug made during prior authorization by a health
insurance issuer or an entity that it contracts with to perform prior authorization on its behalf must be made by a
physician whose specialty focuses on the diagnosis and treatment of the condition for which the prescription
drug was prescribed to treat, provided that prior authorization that does not result in an adverse determination
does not require the involvement of a physician on the part of a health insurance issuer or an entity that it
contracts with to perform prior authorization on its behalf.
(3) If the health insurance issuer or an entity that it contracts with to perform prior authorization on
its behalf makes an adverse determination for a prescription drug during prior authorization, it shall provide a
written adverse determination notice that includes a list of reasonable therapeutic alternatives that are covered
by the insurer's formulary."
- END -
- 2 - Authorized Print Version – HB 399
ENROLLED BILL

I hereby certify that the within bill,
HB 399, originated in the House.
___________________________________________
Chief Clerk of the House
___________________________________________
Speaker of the House
Signed this _______________________________day
of____________________________________, 2025.
___________________________________________
President of the Senate
Signed this _______________________________day
of____________________________________, 2025.

HOUSE BILL NO. 399
INTRODUCED BY J. KARLEN, V. RICCI, E. BUTTREY, J. ETCHART
AN ACT REVISING PRIOR AUTHORIZATION LAWS; PROHIBITING PRIOR AUTHORIZATION FOR ORAL
AND INHALED GENERIC PRESCRIPTION DRUGS; PROHIBITING PRIOR AUTHORIZATION FOR INHALED
PRESCRIPTION DRUGS FOR ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, OR CHRONIC
LUNG DISEASE; PROHIBITING PRIOR AUTHORIZATION FOR INSULIN; REQUIRING INSURERS TO
PROVIDE A LIST OF REASONABLE THERAPEUTIC ALTERNATIVES IF THE INSURER MAKES AN
ADVERSE DETERMINATION FOR A PRESCRIPTION DRUG; AND AMENDING SECTION 33-32-221, MCA.

[DELETED:  H-  P)a)a)a]
[DELETED:  H- )a)a)a)f)A)I]
[DELETED:  D P P A F I R I T A L O R T A I T I M A]